Eloxx Pharmaceuticals

102 articles about Eloxx Pharmaceuticals

• Enrollment in Phase 2 Clinical Trial in Cystic Fibrosis Has Been Resumed in Israel and Europe After Being Paused Temporarily in Response to the COVID-19 Pandemic

  6/17/2020

  Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today announced that enrollment in its Phase 2 clinical trial for ELX-02 i

• Eloxx Pharmaceuticals Reports First Quarter 2020 Financial and Operating Results and Provides Business Update

  5/7/2020

  Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, reported its financial results for the three months ended March 31, 2020 and provided a business update.

• Eloxx Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on May 7, 2020Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

  4/13/2020

  Eloxx Pharmaceuticals, Inc. today announced that it will release its first quarter 2020 financial and operational results and host a conference call and live webcast on Thursday, May 7, 2020. Conference

• 

  Clinical Catch-Up: March 23-27

  3/30/2020

  Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.

• Eloxx Pharmaceuticals Provides Update on the Impact of Novel Coronavirus (COVID-19) on Phase 2 Clinical Trials in Cystic Fibrosis

  3/25/2020

  Enrollment in our Phase 2 Cystic Fibrosis Trials has been paused temporarily in response to the COVID-19 pandemic Cystic Fibrosis patients, especially those with nonsense mutations, are at increased risk of severe illness WALTHAM, Mass., March 25, 2020 (GLOBE NEWSWIRE) -- Eloxx Pharmaceuticals, Inc., (NASDAQ: ELOX) a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mut

• Eloxx Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial and Operating Results and Provides Business Update

  3/5/2020

  Eloxx Pharmaceuticals, Inc. reported its financial results for the three and twelve months ended December 31, 2019 and provided a business update.

• 

  Eloxx Pharma Replaces CEO, Shifts Board to Refocus on Cystic Fibrosis Program

  2/27/2020

  The changes are designed to extend the company’s cash runway to the end of 2021.

• Eloxx Strengthens its Commitment to Cystic Fibrosis Through Reallocating Resources

  2/26/2020

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics to treat cystic fibrosis and other diseases caused by nonsense mutations limiting production of functional proteins, today reaffirms that it expects to report topline data from its Phase 2 cystic fibrosis clinical trial program for ELX-02 during the first half of 2020,

• 

  Clinical Catch-Up: January 13-17

  1/20/2020

  There were plenty of clinical trial announcements this week. Here's a look.

• Eloxx Pharmaceuticals Provides Update on Progress of Its Phase 2 Clinical Programs for ELX-02 and ERSG Pipeline at Biotech Showcase™

  1/14/2020

  Phase 2 cystic fibrosis program for ELX-02 expected to be fully enrolled in the first quarter of 2020 and topline results expected during the first half of 2020

• Eloxx Pharmaceuticals to Present at the Biotech Showcase™ 2020 on January 14, 2020

  12/18/2019

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will provide a corporate update and also participate in a Lunch Plenary Panel titled: “Reshaping the life sciences and healthcare landscape: The impact of pricing, policy and payers”

• Eloxx Pharmaceuticals to Present at the Evercore ISI 2nd Annual HealthCONx on December 4th, 2019

  11/19/2019

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxx, will participate in a fireside chat and host one-on-one meetings with investors at the Evercore ISI 2nd Annual HealthCONx

• Eloxx Pharmaceuticals to Present at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019

  11/18/2019

  Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), today announced that Robert E. Ward, Chairman and Chief Executive Officer of Eloxxwill participate in a fireside chat and host one-on-one meetings with investors at the 31st Annual Piper Jaffray Healthcare Conference on December 3rd, 2019 at the Lotte New York Palace in New York, NY.

• Eloxx Pharmaceuticals Presents New Positive Data for ELX-02 at the American Society of Nephrology (ASN) Kidney Week 2019

  11/7/2019

  Results of our renal impairment study for ELX-02 support the expansion of our research in the kidney beyond nephropathic cystinosis into other areas such as autosomal dominant polycystic kidney disease

• Eloxx Pharmaceuticals Reports Third Quarter 2019 Financial and Operating Results and Provides Business Update

  11/5/2019

  Eloxx Pharmaceuticals, Inc. reported its financial results for the three and nine months ended September 30, 2019 and provided a business update.

• 

  Clinical Catch-Up: October 28-Nov 1

  11/4/2019

  Even clinical trial announcements don’t slow down for Halloween. It was a typically busy week. Here’s a look.

• Eloxx Pharmaceuticals Presents Positive Data for Lead Investigational Drug, ELX-02, at the North American Cystic Fibrosis Conference (NACFC)

  10/31/2019

  Eloxx Pharmaceuticals, Inc. (“Eloxx”), (NASDAQ: ELOX), today announced positive data demonstrating that ELX-02 results in a pronounced increase in both CFTR protein expression and mRNA stability further supporting its proposed mechanism of action, and that it was well tolerated with no serious adverse events in the Phase 1 program.

• SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Eloxx Pharmaceuticals, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors

  10/23/2019

  Purcell Julie & Lefkowitz LLP, a class action law firm dedicated to representing shareholders nationwide, is investigating a potential breach of fiduciary duty claim involving the board of directors of Eloxx Pharmaceuticals, Inc.

• Eloxx Pharmaceuticals to Report Third Quarter 2019 Financial Results and Provide Business Update on November 5, 2019

  10/10/2019

  Company management to host a webcast and conference call to provide a business update and review financial results at 4:30 p.m. ET

• 

  Clinical Catch-Up: September 23-27

  9/30/2019

  It was a moderately busy week for clinical trial news. Here’s a look.